Jane Street Group LLC Purchases 357,891 Shares of Ocugen, Inc. (NASDAQ:OCGN)

Jane Street Group LLC lifted its position in Ocugen, Inc. (NASDAQ:OCGN - Free Report) by 258.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 496,177 shares of the company's stock after buying an additional 357,891 shares during the quarter. Jane Street Group LLC owned approximately 0.17% of Ocugen worth $399,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Virtu Financial LLC purchased a new stake in shares of Ocugen in the fourth quarter worth about $32,000. Tower Research Capital LLC TRC raised its stake in Ocugen by 309.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 39,848 shares of the company's stock valued at $32,000 after purchasing an additional 30,120 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in Ocugen in the fourth quarter valued at approximately $40,000. Two Sigma Securities LLC raised its stake in Ocugen by 92.9% in the fourth quarter. Two Sigma Securities LLC now owns 51,909 shares of the company's stock valued at $42,000 after purchasing an additional 25,004 shares in the last quarter. Finally, Gerber Kawasaki Wealth & Investment Management purchased a new stake in Ocugen in the fourth quarter valued at approximately $56,000. 10.27% of the stock is owned by hedge funds and other institutional investors.

Ocugen Trading Up 0.1%

Shares of OCGN traded up $0.00 during mid-day trading on Monday, reaching $0.84. The company's stock had a trading volume of 3,467,080 shares, compared to its average volume of 4,481,333. The company has a current ratio of 2.58, a quick ratio of 2.58 and a debt-to-equity ratio of 0.04. Ocugen, Inc. has a 52 week low of $0.52 and a 52 week high of $1.98. The company's fifty day moving average price is $0.73 and its two-hundred day moving average price is $0.75. The stock has a market cap of $244.49 million, a PE ratio of -4.65 and a beta of 4.21.

Ocugen (NASDAQ:OCGN - Get Free Report) last issued its earnings results on Friday, May 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%. The firm had revenue of $1.48 million for the quarter. On average, analysts predict that Ocugen, Inc. will post -0.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

OCGN has been the topic of a number of recent analyst reports. Chardan Capital reaffirmed a "buy" rating and issued a $7.00 target price on shares of Ocugen in a research note on Monday, May 12th. HC Wainwright lowered their target price on shares of Ocugen from $8.00 to $7.00 and set a "buy" rating on the stock in a research note on Monday, May 12th.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.